Attgeno AB
PrivateLast Round
Early Funding
Oct 26, 2023
Est. Valuation
$25.77M
Total Funding Raised
$7.44M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Attgeno AB operates in Healthcare & Life Sciences and is based in Solna. Its latest recorded funding round was an Early Funding round in October 2023.
Attgeno AB is a biotechnology company that develops and commercializes innovative nitric oxide-donating drugs for the treatment of pulmonary hypertension.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Attgeno AB Comparables
Compare Attgeno AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Keenova Therapeutics plc | 68% | |
| Claritas Pharmaceuticals Inc | 61% | |
| Cereno Scientific | 59% |
For institutional investors. Book with your work email.
Attgeno AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 26, 2023 | ||||
| Early Funding | Jun 13, 2023 | ||||
| Early Funding | Jul 3, 2022 | ||||
| Grant | Oct 1, 2018 | ||||
| Private Equity | May 22, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Attgeno AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Eir Ventures | Early Funding |
| Swelife | Grant |
| Hadean Ventures | Early Funding, Private Equity |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors grew 89% MoM.
- Mar 2, 2026
Monthly visitors grew 333% MoM, from 81 to 351.
For institutional investors. Book with your work email.
Attgeno AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Attgeno AB's valuation, stock price, and market status.
Is Attgeno AB a public or private company?
Attgeno AB is a private company.
What is the current stock price of Attgeno AB?
Attgeno AB is a private company, so its shares have no public market price. Caplight tracks Attgeno AB's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Attgeno AB worth (valuation)?
Attgeno AB's valuation is estimated at $25.8M based on funding round data.
Can I buy Attgeno AB stock?
Attgeno AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Attgeno AB's last funding round?
Attgeno AB's most recent funding round was Early Funding on October 26, 2023.
Who are the main investors in Attgeno AB?
Key investors in Attgeno AB include Hadean Ventures.
Will Attgeno AB IPO soon?
No public IPO plans have been announced for Attgeno AB.
How can I track Attgeno AB secondary market activity?
Caplight tracks bids, offers, and trades in Attgeno AB's shares on secondary markets.